drugset / Trial / NCT02479308

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308

Phase 1 Completed 129 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.

Timeline

Start
2015-06
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 5461 Unknown Other
Comparator Moxifloxacin Small molecule Oral

Indications

No indication recorded.